A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT03844932 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

235

Enrollment

INDUSTRY

Sponsor class

Stopped The Sublimity Board of Directors carefully evaluated the IA data: the 9.6% treatment remission difference for 75mg BID vs placebo (due to an increase in placebo response rate) was determined not sufficient to continue to fund the study

Conditions

Colitis, Ulcerative

Interventions

DRUG: ST-0529

Sponsor

Sublimity Therapeutics Holdco Limited

Collaborators

[object Object]